Efficacy of memantine on cognitive functions of patients with moderate vascular dementia by Nazish, Saima et al.
Pakistan Journal of
Neurological Sciences (PJNS)
Volume 10 | Issue 1 Article 4
3-2015
Efficacy of memantine on cognitive functions of
patients with moderate vascular dementia
Saima Nazish
Ziauddin University Hospital Karachi
Bashir A Soomro
Ziauddin University Hospital Karachi.
Shafaq Alvi
Ziauddin University Hospital Karachi.
Follow this and additional works at: http://ecommons.aku.edu/pjns
Recommended Citation
Nazish, Saima; Soomro, Bashir A; and Alvi, Shafaq (2015) "Efficacy of memantine on cognitive functions of patients with moderate
vascular dementia," Pakistan Journal of Neurological Sciences (PJNS): Vol. 10: Iss. 1, Article 4.
Available at: http://ecommons.aku.edu/pjns/vol10/iss1/4
EFFICACY OF MEMANTINE ON COGNITIVE FUNCTIONS
OF PATIENTS WITH MODERATE VASCULAR DEMENTIA
Dr Saima Nazish,Dr Bashir A Soomro,Dr Shafaq Alvi
Neurology section, Department of Medicine. Ziauddin university hospital Karachi. 
O R I G I N A L  A R T I C L E
Correspondence to: Dr Saima Nazish, Flat no G3 Fareed Terrace, sec 15A/5,Buffer Zone Karachi. Email:saima_nzsh@yahoo.com
Date of Submission: September 05, 2014, Date of Revision: December 22, 2014, Date of Acceptance: December 29, 2014
ABSTRACT
Introduction: Vascular dementia is a common condition for which there is no effective approved pharmacological 
treatment available. Absence of effective treatment creates a difficult situation for those suffering from the disease, 
their caregivers, and healthcare providers. The objective of this study is todetermine the Efficacy of Memantine on 
cognitive functions in patients with Moderate vascular dementia. Material and methods: This Case series study was 
carried out inthe Neurology Section of department of Medicine Ziauddin University and Hospitals North Nazimabad 
campus, Karachifrom 12th March 2010 to 11th March 2011.90 patients were included, who fulfilled the inclusion 
criteria after taking an informed consent. The SPSS version 11 was applied to the data. Results: There were 55 
(59.1%) males and 38 (40.9%) females. Mean ± standard deviation age 69.7 ± 6.6 years, mean duration of symp-
toms was 1.76 ± 1.1 years. Baseline minimental examination score was 15.14 ± 3.1. Minimental score after 24 
weeks of drug therapy was 17.14 ± 4.1. Efficiency was found in 62 (66.7%) patients. Conclusion: Memantine 
produced only a small benefit in cognition (of uncertain clinical significance) in patients with moderate vascular dementia. 
Data is insufficient to support widespread use of this drug in vascular dementia. Individual patient analysis is needed 
to identify subgroups of patients with vascular dementia who might benefit.
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INTRODUCTION
Anticholinesterase and Memantine are Drugs, which 
specifically treat Alzheimers disease. Although these 
drugs do not halt the disease or reverse existing brain 
damage, they can improve symptoms and slow the 
progression of the disease(1). Many researchers are also 
examining whether these drugs may be useful for treat-
ing other types of dementia (1-3).Improvement of demen-
tia symptoms in clinical trials are assessed in 3 domains.
1. Cognitive end point, cognition is measured by objective test.
2. Functional end point, that is activity of daily living 
3. Global end point, overall clinical response is measured 
by Global assessment. Minimental state examination 
(MMSE) is an objective Tool that is used for screening 
and measuring out come in cognition enhancing drug 
trials. It has a good sensitivity and specificity in detecting 
cognitive impairment with different dementia syndromes 
along with good concurrent validity when compared to 
verbal and performance intellectual quocient of the adult 
intelligence scale(5). Some studies have confirmed the 
reliability and capacity of MMSE to measure cognitive 
improvement following treatment of depression(6) pooled 
trials of cholinesterase inhibitors identified an improve-
ment of 1.4 point on MMSE over 6 months with simal-
tanous small but statistically significant improvements in 
daily life activity an behavioral symptoms(7). Further 
moreSeveral previous studies have shown that Anticho-
linesterase can benefit patients with vascular dementia 
or concurrent Alzheimers disease and cerebrovascular 
disease. A 28 weeks,randomized placebo controlled trial 
on efficacy and tolerability of memantine in the treat-
ment of mild to moderate vascular dementia has shown, 
improvement of 1.8 plus minus 3.51 points in cognition 
scale over base line score in 60% with memantine 
compared with 52% with placebo group, p=0.227(4). As 
vascular dementia acounts for 15 to 20 percent of 
dementia cases worldwide and no effective treatment is 
available for it so, the aim of this study is to determine 
the effects of Memantine on cognitive functions of 
patients with vascular dementia. By knowing this we can 
prescribe drug to improve cognition in patients of vascu-
lar dementia. Therefore, our study will open new horizons 
in the era where dementia is considered untreatable . It 
will also be a positive addition to the available local data 
(9, 10). So that it could be used in future, as there are only 
limited studies done on this topic.
MATERIAL AND METHODS
This Case series study was conducted inout patient 
department of Neurology Section, Department of Medi-
cine Ziauddin University and Hospital North Nazimabad 
campus, Karachi from 12th March 2010 to 11th March 
2011. Sample size was calculated on the basis of 
proportion of previous studies, by using formula which 
inc ludesp=60%,d=10%,1-a lpha=95%,n=93 
patients. Total 120 patients were enrolled, in order to 
compensate for dropouts,non probability purposive 
sampling technique was used. Inclusion criteria 
included patients of either gender of age being greater 
than  60 years, who fulfilled the DSMIV diagnostic 
criteria ofvascular dementia,and were graded as moder-
ate vascular dementia on the basis of MMSE score 
ranging between 10-19 and with the duration of symp-
toms of more than 6 months.Patients with psychiatric 
illness ,history of stroke within prior 28 days or history 
of  myocardial infarction were excluded from study. As 
these patients were deemed unable to make independ-
ent decision due to their decliningcognition, an 
informed consent was taken from their first kins and 
caregivers detailed explanation of the purpose of study, 
effects, side effects of the drug was provided. Patients 
were given Tab Memantine 10mg/day.then followed in 
out patient department by researcher herself for 6 
months, at week 6, 12, 18 and 24. The dose was stepwise 
escalated to 20 mg/day according to patients response 
( in terms of improvement in symptoms ) till maximum 
tolerable gastrointestinal side effectsoccured. Minimen-
tal scoring was done after completion of 6 months of 
drug therapy and this information was entered in 
performa by the researcher. Improvement of >1 point 
from the baseline minimental score was labeled as 
efficacy positive. The data feeding and analysis was 
done on computer package SPSS (Statistical Package 
for Social Science) version 11.0. The results were 
computed as frequency and percentage for gender and 
efficacy, Mean and SD were used for age and  duration 
of disease. Stratification was done with regared to age, 
gender and duration of disease to see the effect of 
these on the out come.
RESULTS
Ninety three patients fulfilling the inclusion criteria were 
included in this study. There were 55 (59.1%) males 
and 38 (40.9%) females (Figure I). Mean± standard 
deviation age 69.7 ± 6.6 years, mean duration of 
symptoms was 1.76 ± 1.1 years (Table I). Base line 
mini mental examination score was 15.14 ± 3.1 (Table 
I). Mini mental score after 24 weeks of drug therapy 
was 17.14 ± 4.1 (Table I). Symptomatic improvement 
was found in 62 (66.7 %) patients (Figure II). Mean age 
of male patients was 69 ± 6.3 years and mean age of 
female patients was 70.61 ± 7.0 years (Table II). Mean 
duration of male patients was 1.61 ± 0.99 years and 
mean duration of female patients was 1.97 ± 1.26 
years. (Table II). Mean base line mini mental examina-
tion score of males was 15.33 ± 3.1 and mean base 
line mini mental of females was 4.87 ± 3.1 (Table II). 
Mini mental examination score after 24 weeks of drug 
therapy of males was 17.3 ± 4.2 and mini mental 
examination score after 24 weeks of drug therapy of 
females was 16.95 ± 3.94 ( Table II). Mean age of 
patient in whom drug was effective was 69.7 ± 6.8 
years, mean duration of symptoms 1.7 ± 1.1 years, 
mean base line mini mental examination score was 
15.6 ± 3 and mini mental examination score after 24 
weeks of drug therapy was 17.13 ± 4.09 (Table III).
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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INTRODUCTION
Anticholinesterase and Memantine are Drugs, which 
specifically treat Alzheimers disease. Although these 
drugs do not halt the disease or reverse existing brain 
damage, they can improve symptoms and slow the 
progression of the disease(1). Many researchers are also 
examining whether these drugs may be useful for treat-
ing other types of dementia (1-3).Improvement of demen-
tia symptoms in clinical trials are assessed in 3 domains.
1. Cognitive end point, cognition is measured by objective test.
2. Functional end point, that is activity of daily living 
3. Global end point, overall clinical response is measured 
by Global assessment. Minimental state examination 
(MMSE) is an objective Tool that is used for screening 
and measuring out come in cognition enhancing drug 
trials. It has a good sensitivity and specificity in detecting 
cognitive impairment with different dementia syndromes 
along with good concurrent validity when compared to 
verbal and performance intellectual quocient of the adult 
intelligence scale(5). Some studies have confirmed the 
reliability and capacity of MMSE to measure cognitive 
improvement following treatment of depression(6) pooled 
trials of cholinesterase inhibitors identified an improve-
ment of 1.4 point on MMSE over 6 months with simal-
tanous small but statistically significant improvements in 
daily life activity an behavioral symptoms(7). Further 
moreSeveral previous studies have shown that Anticho-
linesterase can benefit patients with vascular dementia 
or concurrent Alzheimers disease and cerebrovascular 
disease. A 28 weeks,randomized placebo controlled trial 
on efficacy and tolerability of memantine in the treat-
ment of mild to moderate vascular dementia has shown, 
improvement of 1.8 plus minus 3.51 points in cognition 
scale over base line score in 60% with memantine 
compared with 52% with placebo group, p=0.227(4). As 
vascular dementia acounts for 15 to 20 percent of 
dementia cases worldwide and no effective treatment is 
available for it so, the aim of this study is to determine 
the effects of Memantine on cognitive functions of 
patients with vascular dementia. By knowing this we can 
prescribe drug to improve cognition in patients of vascu-
lar dementia. Therefore, our study will open new horizons 
in the era where dementia is considered untreatable . It 
will also be a positive addition to the available local data 
(9, 10). So that it could be used in future, as there are only 
limited studies done on this topic.
MATERIAL AND METHODS
This Case series study was conducted inout patient 
department of Neurology Section, Department of Medi-
cine Ziauddin University and Hospital North Nazimabad 
campus, Karachi from 12th March 2010 to 11th March 
2011. Sample size was calculated on the basis of 
proportion of previous studies, by using formula which 
inc ludesp=60%,d=10%,1-a lpha=95%,n=93 
patients. Total 120 patients were enrolled, in order to 
compensate for dropouts,non probability purposive 
sampling technique was used. Inclusion criteria 
included patients of either gender of age being greater 
than  60 years, who fulfilled the DSMIV diagnostic 
criteria ofvascular dementia,and were graded as moder-
ate vascular dementia on the basis of MMSE score 
ranging between 10-19 and with the duration of symp-
toms of more than 6 months.Patients with psychiatric 
illness ,history of stroke within prior 28 days or history 
of  myocardial infarction were excluded from study. As 
these patients were deemed unable to make independ-
ent decision due to their decliningcognition, an 
informed consent was taken from their first kins and 
caregivers detailed explanation of the purpose of study, 
effects, side effects of the drug was provided. Patients 
were given Tab Memantine 10mg/day.then followed in 
out patient department by researcher herself for 6 
months, at week 6, 12, 18 and 24. The dose was stepwise 
escalated to 20 mg/day according to patients response 
( in terms of improvement in symptoms ) till maximum 
tolerable gastrointestinal side effectsoccured. Minimen-
tal scoring was done after completion of 6 months of 
drug therapy and this information was entered in 
performa by the researcher. Improvement of >1 point 
from the baseline minimental score was labeled as 
efficacy positive. The data feeding and analysis was 
done on computer package SPSS (Statistical Package 
for Social Science) version 11.0. The results were 
computed as frequency and percentage for gender and 
efficacy, Mean and SD were used for age and  duration 
of disease. Stratification was done with regared to age, 
gender and duration of disease to see the effect of 
these on the out come.
RESULTS
Ninety three patients fulfilling the inclusion criteria were 
included in this study. There were 55 (59.1%) males 
and 38 (40.9%) females (Figure I). Mean± standard 
deviation age 69.7 ± 6.6 years, mean duration of 
symptoms was 1.76 ± 1.1 years (Table I). Base line 
mini mental examination score was 15.14 ± 3.1 (Table 
I). Mini mental score after 24 weeks of drug therapy 
was 17.14 ± 4.1 (Table I). Symptomatic improvement 
was found in 62 (66.7 %) patients (Figure II). Mean age 
of male patients was 69 ± 6.3 years and mean age of 
female patients was 70.61 ± 7.0 years (Table II). Mean 
duration of male patients was 1.61 ± 0.99 years and 
mean duration of female patients was 1.97 ± 1.26 
years. (Table II). Mean base line mini mental examina-
tion score of males was 15.33 ± 3.1 and mean base 
line mini mental of females was 4.87 ± 3.1 (Table II). 
Mini mental examination score after 24 weeks of drug 
therapy of males was 17.3 ± 4.2 and mini mental 
examination score after 24 weeks of drug therapy of 
females was 16.95 ± 3.94 ( Table II). Mean age of 
patient in whom drug was effective was 69.7 ± 6.8 
years, mean duration of symptoms 1.7 ± 1.1 years, 
mean base line mini mental examination score was 
15.6 ± 3 and mini mental examination score after 24 
weeks of drug therapy was 17.13 ± 4.09 (Table III).
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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Variable                                     Minimum              Maximum               Mean             Std. Deviation
Age/years                                       61                        87                    69.7                     6.6
Duration of symptoms                       1                          6                      1.8                      1.1
Baseline minimental                         9                         19                    15.1                     3.1
examination score                             
Minimental examination                    8                         29                    17.1                     4.1
score after 24 weeks of
drug therapy
Gender                    Age           Duration            Baseline minimental     Minimental examination score
                                            of symptoms      examination score         after 24 weeks of drug therapy
Male         Mean       69            1.6                   15.3                            17.3
               SD          6.3           1                      3.1                              4.2
Female      Mean       70.6         2                      14.9                            16.9
               SD          7              1.3                   3.1                              3.9
p value                    0.483       0.040               0.266                          0.696
TABLE I ANALYSIS OF DESCRIPTIVE STATISTICS
TABLE II ANALYSIS OF DESCRIPTIVE STATISTICS AMONG THE GENDER
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DISCUSSION
Vascular dementia is the second most common cause 
of dementia after Alzheimers disease in aging population (9). 
It is a heterogenous condition including single large 
infarct,multiple small infarcts along with diffuse 
whitematter ischemic lesions (12). It is evident that 
stroke risk factors such as Hypertension, Diabetesmeli-
tis, Myocardialinfarction and Smoking have a contribu-
tory effect on Alzheimers disease and there is also an 
overlap in pathphysiology of  both Alzheimers and 
vascular dementia (13, 14). Memantine produces its effect 
by being aN methyl D Aspartate receptor antagonist. 
Since NMDA Receptor mediated excitotoxic nerve cell 
death, is considered to be of paramount importance in 
ischemic cell death. It is alsoneuroprotectiveand 
consider potentialy therapeutic in many neuropsychiat-
ric diseases as well(15). 
FIGURE I ANALYSIS OF GENDER
It has been approved by FDA as monotherpy and in 
combination with anticholinesterase for moderate to 
severe  Alzeimers disease. On the basis of overlap in 
pathophsiology of Alzheimers disease and vascular 
dementia,its considered quite promising to use 
Memantinefor later. A 28 weeks placebo based triall 
tested Memantinein dose of 20 mg/day dose.Data 
analysis showed significant improvement in cognitive 
functions from baseline over placebo with no change 
inclinical global scale (16). An other pooled analysis of 6 
months clinical trial showed cognitive improvement 
(using the ADAD-cog). patientswho receivedMeman-
tine, had statistically significant better outcome and 
mild adverse effects.(17). A study of Memantine/chEI  
combination therapy had similar results and 
Conclusion(18). On basis of these studies one can 
conclude  that memantine has a potential to treat 
vascular dementia but at the same time they also 
indicate that there is in- adequate data available in this 
regard and further studies are needed to consider. 
FIGURE II ANALYSIS OF SYMPTOMATIC IMPROVEMENT
SYMPTOMATIC IMPROVEMENT
In our study we did not find statistically significant 
improvement in cognitive function of patients with mod-
erate vascular dementia. On further review of literature 
it has been observed that there are relatively few 
studies on the treatment of vascular dementia with 
several  compounds of  different mechanism of actions 
that showed mild efficiency in cognitive functions of 
these patients.So probably its not only cytotoxic cell 
death, but a number of other different mechanisms 
which play role in etiopathgenesis of vascular 
dementia.Micro array analysis of messenger RNA for 
monitoring of behavior of large number of genes may 
also reveal complex cascade of reactions  for  regula-
tion of  nerve cell susceptibility to injury(19). In future  
otherneuroprotective drugs with simultaneous targeting 
effects on multiple events related to cell death and 
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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TABLE III ANALYSIS OF DESCRIPTIVE STATISTICS AMONG THE EFFICACY
Symptomatic            Age           Duration            Baseline minimental     Minimental examination score 
improvement                            of symptoms      examination score         after 24 weeks of drug therapy
Yes           Mean       69.7         1.7                   15.6                            18.1
               SD          6.8           1.1                   3                                 3.7
No            Mean       69.7         1.8                   14.2                            15.3
               SD          6.4           1.2                   4                                 4.2
p value                    0.808       0.775               0.002                          0.057
certain transcription related genes are expected to be 
very effective in treatment of vascular dementia. 
CONCLUSION
Memantine produces small benefits in cognition of 
uncertain clinical significance in patients with mild to 
moderate vascular dementia. Data is  insufficient to 
support widespread use of this  drugs in vascular demen-
tia. Individual patient analysis is needed to identify 
subgroups of patients with vascular dementia who might 
benefit from it.
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DISCUSSION
Vascular dementia is the second most common cause 
of dementia after Alzheimers disease in aging population (9). 
It is a heterogenous condition including single large 
infarct,multiple small infarcts along with diffuse 
whitematter ischemic lesions (12). It is evident that 
stroke risk factors such as Hypertension, Diabetesmeli-
tis, Myocardialinfarction and Smoking have a contribu-
tory effect on Alzheimers disease and there is also an 
overlap in pathphysiology of  both Alzheimers and 
vascular dementia (13, 14). Memantine produces its effect 
by being aN methyl D Aspartate receptor antagonist. 
Since NMDA Receptor mediated excitotoxic nerve cell 
death, is considered to be of paramount importance in 
ischemic cell death. It is alsoneuroprotectiveand 
consider potentialy therapeutic in many neuropsychiat-
ric diseases as well(15). 
FIGURE I ANALYSIS OF GENDER
It has been approved by FDA as monotherpy and in 
combination with anticholinesterase for moderate to 
severe  Alzeimers disease. On the basis of overlap in 
pathophsiology of Alzheimers disease and vascular 
dementia,its considered quite promising to use 
Memantinefor later. A 28 weeks placebo based triall 
tested Memantinein dose of 20 mg/day dose.Data 
analysis showed significant improvement in cognitive 
functions from baseline over placebo with no change 
inclinical global scale (16). An other pooled analysis of 6 
months clinical trial showed cognitive improvement 
(using the ADAD-cog). patientswho receivedMeman-
tine, had statistically significant better outcome and 
mild adverse effects.(17). A study of Memantine/chEI  
combination therapy had similar results and 
Conclusion(18). On basis of these studies one can 
conclude  that memantine has a potential to treat 
vascular dementia but at the same time they also 
indicate that there is in- adequate data available in this 
regard and further studies are needed to consider. 
FIGURE II ANALYSIS OF SYMPTOMATIC IMPROVEMENT
SYMPTOMATIC IMPROVEMENT
In our study we did not find statistically significant 
improvement in cognitive function of patients with mod-
erate vascular dementia. On further review of literature 
it has been observed that there are relatively few 
studies on the treatment of vascular dementia with 
several  compounds of  different mechanism of actions 
that showed mild efficiency in cognitive functions of 
these patients.So probably its not only cytotoxic cell 
death, but a number of other different mechanisms 
which play role in etiopathgenesis of vascular 
dementia.Micro array analysis of messenger RNA for 
monitoring of behavior of large number of genes may 
also reveal complex cascade of reactions  for  regula-
tion of  nerve cell susceptibility to injury(19). In future  
otherneuroprotective drugs with simultaneous targeting 
effects on multiple events related to cell death and 
INTRODUCTION
Stroke is one of the most leading causes of mortality 
and disability in the world. (1) Many patients are left with 
residual cognitive deficits such as personality disorders, 
depression and memory loss after acute phase of 
stroke (2, 3). Post stroke dementia (PSD) is the second 
most common cause of dementia (4) and one of the 
main causes of dependency in survivors and includes 
any dementia after a stroke, irrespective of its cause (5). 
In Europe and North America, Alzheimer's disease 
predominates over PSD in a 2:1 ratio; in contrast, in 
some Asian countries PSD accounts for almost 50% of 
all dementias (6). Its prevalence ranges from 6 to 32% (7) 
and it has been found to be higher than previously 
expected, and a stroke increases the risk of dementia 4 
to 12 times (8). The diagnosis of PSD is based on the 
patient history, the clinical evaluation and neuroimaging 
(9), and it is   associated with high rates morbidity and 
mortality (2). Then, it is important to determine its risk 
factors. Some demographic, genetic and lesion-related 
radiological factors have been reported to predict 
dementia in stroke patients, but there has not been a 
consensus about them  (10, 11). Realizing the importance 
of research in this filed and lack of any published 
studies  about PSD from Iran , we decided to evaluate 
the prevalence of PSD  and some of  its putative  risk  
factors. To our knowledge, this is the first hospital-
based study among Iranian population about PSD.
METHODS 
1. Subjects 
This cross-sectional study was conducted on 151 
patients with first-ever stroke in Rafsanjan (south of 
Iran). Patients with a clinical suspicion of stroke under-
went neuroimaging (CT scan and MRI) and the diagnosis 
was confirmed by them. All patients with history of any 
underling disease especially dementia and mild cognitive 
impairment were excluded from the study except 
patients with ischemic heart disease (IHD), diabetes 
(DM), hypertension (HTN) and hyperlipidemia (HLP). 
Other exclusion criteria were history of opium or other 
substance addiction, inadequate vision and hearing, 
aphasia   any drug consumption (except drugs were 
used for treatment of IHD, DM, HTN, HLP) such as 
antipsychotic and anti depressant. The ethics committee 
of Yazd branch of Islamic Azad University had confirmed 
the research. 
2. Clinical characteristics
Following information was collected for each patient: 
baseline demographics (age, gender and educational 
status), stroke type according to Oxfordshire Community 
Stroke Project Classification. The subjects were 
screened for PSD using the DSM-IV at three months.
3. Statistical analysis
To analyze the data, descriptive statistics, and 
chi-square test were used and p≤0.05 was considered   
statistically significant.
RESULTS 
In our study, 71(47%) patients were male and the rest 
were80 (53%) female. Mean age of men and women 
were 65.5 and 66.5 years, respectively. 35 (23.2%)   
patients had PSD after three months. 70.6 % of 
patients were 60 years old or more. 88.7% of patients 
had ischemic infarction and the others had hemor-
rhagic stroke. The most frequent lesion locations were 
temporal, frontal and parietal lobes respectively. There 
was no significant statistical difference between PSD 
and sex, age, educational status, lesion location and 
kind of stroke. (Table 1)
Table1: Frequency of risk factors in patients 
CONCLUSION
In our hospital-based study prevalence of PSD was 
23.2 % . This finding shows that a significant portion of 
patients with stroke are prone to PSD. We did not find 
any published article about PSD concerning the Iranian 
population; it seems that in Iranian population, our 
study is the first in this field but many studies have been 
conducted in other countries. Prevalence of PSD is 
reported to be between 7% and 41%, (10). Some studies 
show the same frequency of PSD as our study, such as 
those conducted in Italy (24.6%) and America (26.3%) 
(12,13 ) where as others show lower prevalence such as 
Portugal( 5.9% ) and Taiwan( 9.2%) (14, 15) or higher in 
Finland (31.8%) (16). In a systematic review ,the prevalence 
of post stroke memory dysfunction varied from 23% to 
55% 3 months post stroke, which declined from 11% to 
31% 1 year post stroke.(17 ). The prevalence of dementia 
among people with a history of stroke is similar to that 
observed in subjects 10 years older without a history of 
stroke (18). Also, several studies have confirmed that 
stroke doubles the probability of developing dementia 
and that risk is higher in the first 6-12 months and in a 
community based study done over 25 years, the cumu-
lative incidence of PSD was 7% after 1 year, 10% after 
3 years, 15% after 5 years, 23% after 10 years, and 
48% after 25 years (19 ) These discrepancies may be   
related to different population studies, different criteria 
used for the diagnosis of dementia  and different time 
interval between stroke and the neuropsychological 
assessment (20). Although, stroke was recognized as an 
important cause of dementia more than a century ago 
(21), many aspects of PSD pathophysiology are not clear. 
The causes of PSD are multifactorial and involve 
neuronal networks needed for memory (22). Disturbance 
in some neurotransmitters (6), genetic factors (23), direct 
neuronal damage and impaired vascular autoregulatory 
mechanisms are some factors involved in PSD pato-
physiology. (2, 24, 25) Our results showed that PSD can be 
seen in both ischemic and hemorrhagic lesions. The 
risk and severity of cognitive disturbances occurring 
after a stroke do not seem to be influenced by type of   
stroke (ischemic or hemorrhagic) (8, 13, 14). In most 
studies such as ours, no gender specifity was observed 
(15,21). Similarly, many studies did not find any relation-
ship between location of the vascular lesion and PSD 
(14,15,21). Higher educational attainment has been found 
to be a protective factor for PSD (5) however, we could 
not ascertain this effect in our study and neither could 
the research performed in Spain (21). Although we did 
not find a relationship between age and dementia, 
some have studies suggested an association between 
the two (11, 21). It should be mentioned that  controversies 
about age, sex, location of lesion and educational 
status are frequent(7 ,11), and some factors such as  
dysphasia, hemiparesis, hemianopia (10), silent infarcts, 
cortical cerebral atrophy (26) medial temporal lobe atrophy 
and white matter changes , have been associated with 
an increased risk to develop PSD in some studies(19). 
Our study had some limitations. First, our study was a 
cross-sectional study. Second; we fallowed the patients 
only three months. Third, patients with aphasia were 
excluded from our study. These limitations may have 
some effects on the results. In conclusion, our study 
showed high prevalence of PSD in Iranian population. 
Both ischemic and hemorrhagic lesions have a similar 
effect on PSD and early recognition and treatment of 
PSD risk factors will definitely improve the quality of life 
of the patients.  
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certain transcription related genes are expected to be 
very effective in treatment of vascular dementia. 
CONCLUSION
Memantine produces small benefits in cognition of 
uncertain clinical significance in patients with mild to 
moderate vascular dementia. Data is  insufficient to 
support widespread use of this  drugs in vascular demen-
tia. Individual patient analysis is needed to identify 
subgroups of patients with vascular dementia who might 
benefit from it.
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